ArticleNature2025
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.Nature reviews. Clinical oncology · 2026Review
- Emerging frontiers in adoptive cell therapies: engineering innovations, current challenges, and manufacturing perspectives.Molecular biology reports · 2026Review
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- Donor-complementary prime editing enables precise kilobase and library-compatible DNA insertions.Nature biotechnology · 2026Article
- From Delivery to Design: Site-Specific Genome Engineering for Next-Generation CAR T-Cell Therapy.Biomedicines · 2026Review
- Next-generation programmable cell therapies for precision medicine.Nature reviews. Genetics · 2026Review
- Virus infections and cancers: from mechanisms to therapeutics.Molecular biomedicine · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Progress in the development of cytokine armoured CAR T cells.Nature reviews. Immunology · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy.Science advances · 2026Article
- The genome takes the wheel: CAR T with built-in circuits.Immuno-oncology technology · 2026Article
- Covalent tumor anchoring spatially orchestrates antitumor immunity.bioRxiv : the preprint server for biology · 2026Article
- Non-viral targeted integration of large DNA in primary human T cells independent of double-stranded DNA breaks.Nature biomedical engineering · 2026Article
- In vivo CAR-T therapy: from molecular design to precision delivery.Journal of nanobiotechnology · 2026Review
- PD-L1-Binding Antigen Presenters: Redirecting Vaccine-Induced Antibodies for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Auto-inducible expression of chimeric antigen receptor T cells using the NR4A1 promoter.Immunology and cell biology · 2026Article
- High-content CRISPR activation screens identify synthetically lethal RNA-based mechanisms to sensitize cancer cells to targeted T cell cytotoxicity.Nature genetics · 2026Article
Corrections and comments
- Commented on by
Authors and funding
34 authors.
Amanda X Y Chen *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Amanda.chen@petermac.org.
Kah Min Yap *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. kahmin.yap@petermac.org.ORCID 0000-0001-5009-9895
Joelle S KimCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-9213-6180
Kevin SekCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-4634-7600
Yu-Kuan HuangCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-2262-7069
Phoebe A DunbarCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Volker WiebkingDepartment of Pediatrics, Stanford University, Stanford, CA, USA.ORCID 0000-0002-9429-5254
Jesse D ArmitageSchool of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia.
Isabelle MunozCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-6510-5696
Kirsten L ToddCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-3903-166X
Emily B DerrickCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-7191-3948
Dat NguyenCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Junming TongCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0009-0006-6454-8704
Cheok Weng ChanCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Thang X HoangCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Katherine M AudsleyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Marit J van ElsasCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-9955-6356
Jim MiddelburgCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-4797-9653
Joel N LeeCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Maria N de MenezesCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-3231-0620
Thomas J ColeCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jasmine LiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Christina SchefflerCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-3731-6204
Andrew M ScottOlivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Laura K MackayDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-8496-6632
Jason WaithmanSchool of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia.ORCID 0000-0003-4940-0155
Jane OliaroCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-2097-6428
Simon J HarrisonSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-4555-6582
Ian A ParishCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-3528-478X
Junyun LaiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-5884-2786
Matthew H PorteusDepartment of Pediatrics, Stanford University, Stanford, CA, USA.ORCID 0000-0002-3850-4648
Imran G HouseCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Phillip K DarcyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Phil.darcy@petermac.org.ORCID 0000-0002-5303-9561
Paul A BeavisCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Paul.beavis@petermac.org.ORCID 0000-0002-2116-013X
Funding
National Health and Medical Research CouncilUniversity of Melbourne research scholarship
Abstract
The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumours is limited by immunosuppression and antigen heterogeneity
Indexed as
Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorCRISPR-Cas SystemsFemaleGene Knock-In TechniquesHumansInterleukin-12Interleukin-2MaleMicePromoter Regions, GeneticTransgenesInterleukin-12Interleukin-2Receptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.